Skip to content
Subscriber Only

Covid-Vaccine Developer in India Plans to Boost Capacity by 70%

  • Cadila expects phase II test data by November end, MD says
  • Cadila is one of two companies developing an Indian vaccine
Updated on

Cadila Healthcare Ltd., one of two Indian drugmakers racing to develop an indigenous Covid-19 vaccine, is in talks with potential partners to ramp up production capacity if its candidate passes human clinical trials.

The Ahmedabad-based firm is looking to hire contract manufacturers for an additional 50 million to 70 million doses of its plasmid DNA vaccine, on top of the 100 million that will come from its own capacity, according to Managing Director Sharvil Patel. He declined to name the companies and the amount Cadila has invested in developing the vaccine.